12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Tyverb lapatinib regulatory update

EMA's CHMP issued a positive opinion recommending approval of Tyverb lapatinib from GlaxoSmithKline in combination with trastuzumab in patients with hormone receptor-negative metastatic breast cancer that has progressed on prior trastuzumab therapy in combination with chemotherapy. GSK markets...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >